Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib vs imatinib + peginterferon alfa-2b in newly diagnosed non-high-risk CML
2004-002504-15Phase 2Completed
- Sponsor
- Nordic CML Study Group
- Start
- Aug 2004
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of imatinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML) (3 arms), sponsored by Nordic CML Study Group. Primary endpoint: Primary molecular response endpoint. Started Aug 2004; status: completed.
02
Drugs
imatinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2004-002504-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002504-15.